Newsbenzinga
Odyssey Therapeutics Reports 27% Clinical Remission At 20mg In Phase 2a Ulcerative Colitis Trial Of OD-001, Meets Primary Endpoint
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Comments —
Loading comments…